Please ensure Javascript is enabled for purposes of website accessibility

Why Orchard Therapeutics Stock Is Jumping Today

By Prosper Junior Bakiny - Feb 9, 2021 at 2:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company released some promising data from a pair of proof-of-concept studies.

What happened?

Shares of gene-therapy specialist Orchard Therapeutics (ORTX 1.01%) were trading sharply higher on Tuesday after the company released updates on two of its candidate treatments. As of 2:30 p.m. EST, Orchard stock was up by 10.7%, after having been up by as much as 21.9% earlier in the session.

So what

Orchard Therapeutics focuses on developing treatments for rare diseases with unmet needs. The company's candidate OTL-203 is a potential therapy for mucopolysaccharidosis type I (MPS-I), a rare and progressively debilitating disorder. Patients with MPS-I fall into one of two categories: Those with the so-called Hurler subtype (MPS-IH) suffer from such symptoms as neurocognitive impairment and skeletal deformities, leading to impaired growth in early childhood.

Treatment options for MPS-IH are currently limited. In a proof-of-concept study that included eight patients with the condition, OTL-203 was generally well tolerated and showed encouraging efficacy. In particular, patients treated with OTL-203 showed stable cognitive performance, stable motor function, and improved range of motion compared to their conditions prior to treatment, among other improvements.

Upward pointing arrows on a blackboard.

Image source: Getty Images.

Meanwhile, Orchard Therapeutics also reported preliminary results from a proof-of-concept study for OTL-201. This experimental treatment targets patients with mucopolysaccharidosis type IIIA (MPS-IIIA), a rare and progressive disorder that affects the nervous system.

Three patients participated in that study, and OTL-201 was well tolerated by them. The biotech also reported encouraging biomarker data from this study. It will host a webinar at 4:30 p.m. EST Tuesday to review and discuss this data.

Now what

It is too early to say what these results might mean for shareholders. Obviously, if Orchard Therapeutics goes on to market these treatments, it would be a big deal for the healthcare company. On the other hand, it still has a long way to go before that happens, if it happens at all, since OTL-201 and OTL-203 could still fail to prove sufficiently effective to pass regulatory muster in larger clinical trials.

It's worth monitoring the development of these programs, but there are other reasons to consider purchasing shares of Orchard Therapeutics. These include the recent approval of Libmeldy in Europe as a treatment for metachromatic leukodystrophy (MLD). Libmeldy is the first therapy approved for early-onset MLD, and the company said it would launch the treatment during the first half of 2021. This  will improve Orchard Therapeutics financial situation significantly, and help the company fund its clinical trials for its promising pipeline candidates. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Orchard Therapeutics plc Stock Quote
Orchard Therapeutics plc
$0.56 (1.01%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.